271 related articles for article (PubMed ID: 26847364)
1. [Current therapeutic strategies for diffuse large B‑cell lymphoma].
Pfreundschuh M
Internist (Berl); 2016 Mar; 57(3):214-21. PubMed ID: 26847364
[TBL] [Abstract][Full Text] [Related]
2. Management of diffuse large B-cell lymphoma (DLBCL).
Kubuschok B; Held G; Pfreundschuh M
Cancer Treat Res; 2015; 165():271-88. PubMed ID: 25655614
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
4. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
6. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray in a subset of South African patients with DLBCL.
Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.
Vaidya R; Witzig TE
Ann Oncol; 2014 Nov; 25(11):2124-2133. PubMed ID: 24625454
[TBL] [Abstract][Full Text] [Related]
9. Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.
Rigacci L; Puccini B; Iovino L; Martelli M; Finolezzi E; DI Lollo S; Doria M; Bosi A
J Chemother; 2011 Aug; 23(4):227-31. PubMed ID: 21803701
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
11. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
13. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH; Connors JM
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
[TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
15. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
16. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
[TBL] [Abstract][Full Text] [Related]
17. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
[TBL] [Abstract][Full Text] [Related]
18. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
19. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
[TBL] [Abstract][Full Text] [Related]
20. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]